加替沙星联合异烟肼、利福平、比嗪酰胺、乙胺丁醇治疗新发结核性胸膜炎临床研究

Tuberculous Pleurisy by jointing Gatifloxacin mesylate and Isoniazid、Rifampin、pyrazinamide、Ethambutol

目的评价加替沙星联合异烟肼、利福平、比嗪酰胺、乙胺丁胺治疗新发结核性胸膜炎的疗效。方法将新发结核性胸膜炎患者随机分为两组,治疗组采用加替沙星联合异烟肼、利福平、比嗪酰胺、乙胺丁醇治疗142例与同期应用异烟肼、利福平、比嗪酰胺、乙胺丁醇方案组142例对照评价临床疗效及不良反应。结果胸水的吸收、治愈、胸膜的粘连情况以及复发率,(P>0.05)。治疗组疗效优于对照组。两组因不良反应停药对照无差别。结论加替沙星联合异烟肼、利福平、比嗪酰胺、乙胺丁醇治疗新发结核性胸膜炎取得更好疗效,副反应无明显增加。

Objective To evaluate the effects of the treatment of new Tuberculous Pleurisy by jointing Gatifloxacin mesylate and Isoniazid、Rifampin、pyrazinamide、Ethambutol. Methods Divide new tuberculous pleurisy patients randomly into two groups. The treatment group treats 142 cases of patients by jointing Gatifloxacin mesylate and Isoniazid、Rifampin、pyrazinamide、Ethambutol, while the other group treats142 cases of patients only by using Isoniazid、Rifampin、pyrazinamide、Ethambutol,then compare and evaluate their clinical efficacy and adverse reactions. Results The curative effect of treatment group in pleural effusion absorption, cure and pleural adhesion and the recurrence rate,（p 0.05）is better than the control group. But there is no difference in the two groups of discontinuation due to adverse reactions to contrast. Conclusions The treatment of new Tuberculous Pleurisy by jointing Gatifloxacin mesylate and Isoniazid、Rifampin、pyrazinamide、Ethambutol has got better results and there is no obvious increase in adverse reactions.